J&J/Boston Sci battle persists
This article was originally published in The Gray Sheet
A federal judge allows Johnson & Johnson to pursue a breach of contract claim against Boston Scientific alleging Guidant violated its 2004 merger deal with J&J when its shareholders decided to be acquired by Boston Scientific instead. In an Aug. 29 1ruling, Southern District of New York Judge Gerard Lynch denied Boston Scientific/Guidant's motion to dismiss the breach of contract claims initiated in October 2006 by J&J as part of a $5.5 billion suit. However, he did dismiss J&J's claims that Boston Scientific improperly interfered with J&J's efforts to buy Guidant and that Guidant breached its "implied duty of good faith and fair dealing" when it decided to accept Boston Scientific's merger offer (2"The Gray Sheet' Oct. 2, 2006, p. 6). The judge also dismissed all of J&J's claims against Abbott Laboratories, whose acquisition of Guidant's stent business helped fund Boston Scientific's Guidant purchase and made it easier for antitrust regulators to clear the deal...
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.